MacroGenics reports phase 1 data for MGC026 in solid tumors

🇺🇸 Investing.com (US) —
MacroGenics reports phase 1 data for MGC026 in solid tumors

AI Summary

MacroGenics reported Phase 1 clinical data for MGC026, a drug candidate being studied for solid tumors. The early-stage results add evidence to the candidate's clinical development but do not establish efficacy or safety beyond the reported trial findings.

Markets Health MacroGenics MGC026 Phase 1 clinical trial solid tumors oncology

Read original source →